About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

New Practice Standard for Men With Prostate Cancer

by Mohamed Fathima S on February 17, 2019 at 8:47 AM
Font : A-A+

New Practice Standard for Men With Prostate Cancer

Hypofractionated radiotherapy schedule (H-RT) is a treatment schedule that delivers a total dose of radiotherapy in a shorter time and should be considered as a new practice standard for men with low-risk prostate cancer. It is as better as the conventional radiotherapy schedule (C-RT) in maintaining bowel, sexual and general quality of life (QOL) and also improves anxiety and depression in men.

NRG-RTOG 0415, a phase III non-inferiority trial compared two fractionation schedules for men with low risk prostate cancer. A total of 1,092 men from the United States, Canada, and Switzerland were randomly assigned to one out of two treatment schedules. Men on the first treatment arm received C-RT at 73.8 Gy in 41 fractions over the course of 8.2 weeks. Men on the second treatment arm received H-RT at 70 Gy in 28 fractions over the course of 5.6 weeks. 962 patients consented to participating in the QOL study.

Advertisement


Patients on both arms were assessed at baseline, 6, 12, 24, and 60 months through the Expanded Prostate Index Composite (EPIC) for bowel, urinary, sexual and hormone domains, the Hopkins Symptom Checklist (HSCL) measuring anxiety and depression, and the Eq5D measuring QOL. There were no statistically significant differences in arms at any point for HSCL and Eq5D as well as no differences in physician reported grade three or greater gastrointestinal or genitourinary adverse events (AEs). There were no statistically significant differences in change score between arms with respect to the EPIC domain scores, except at 12 months with the H-RT arm exhibiting a larger decline in the bowel domain. However, this decline did not meet the a priori threshold of an effect size of 0.5 for clinical significance.

"These results provide a tipping point of evidence, when added to similar trials, that a hypofractionated treatment schedule should be the standard of care for men with low risk prostate cancer who choose among all options to be treated with radiotherapy. The primary outcomes of NRG-RTOG 0415 demonstrated no difference in progression and survival between arms, and the results here confirm that there are also no differences in the important outcomes to patient of adverse events, quality of life, and resources utilized," stated Deborah W. Bruner, RN, PhD, FAAN, the Emory University Senior Vice President for Research and the lead author of the NRG-RTOG 0415 manuscript. "The most frequently patient-cited disadvantage of radiotherapy is the long duration of therapy. This treatment would be more convenient for these men, would mean a decrease in the hours spent in treatment and away from family or work, and would cost them less."
Advertisement

EPIC compliance rates ranged from 89.7% at baseline, 66.0% at 1 year, 60.8% at 2 years, to 55.5% at 5 years and these rates were similar for the HSCL-25 and Eq5D.

Outcomes from NRG-RTOG 0415 support the evidence that H-RT should be considered standard of care and negates the argument that reduced treatment duration equates to clinically meaningful increased AEs and decreased QOL.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
First Dose of COVID-19 Vaccines May Improve Mental Health
Printed Temperature Sensors help with Continuous Temperature Monitoring
Health Benefits of Giloy
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Prostate Cancer Cancer and Homeopathy Trans-Urethral Resection of the Prostate Prostate Cancer Facts Cancer Facts Cancer Tattoos A Body Art Prostate Cancer: Treatment Options Prostate Specific Antigen [PSA] Nutrition All Men Need 

Recommended Reading
Prostate Cancer
This cancer affects men over the age of 50 years and screening with rectal examination and PSA can ....
Drugs for Prostate Cancer
Prostate cancer is the main cause of cancer death in men. One of the treatment method includes ......
Decipher Test for Prostate Cancer
Decipher test a genomic test for prostate cancer that determines the aggressiveness of the cancer .....
Brachytherapy for Prostate Cancer
Learn about two different types of brachytherapy used for treating prostate cancer. Get information ...
Nutrition All Men Need
Everyone requires good nutrition, be it man, woman, child or elderly. However, nutrition that men ne...
Prostate Cancer: Treatment Options
Treatment options of prostate cancer includes waiting, surgery, radiation, hormone therapy, chemothe...
Prostate Specific Antigen [PSA]
PSA blood test is specific to prostate gland but not necessarily a cancer specific test but is commo...
Tattoos A Body Art
Tattoos are a rage among college students who sport it for the ‘cool dude’ or ‘cool babe’ look...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use